0.5719 USD
-0.05 (-8.25%)
0.56 USD
-0.01 (-2.08%)
Overall LGVN gets a fundamental rating of 3 out of 10. We evaluated LGVN against 528 industry peers in the Biotechnology industry. The financial health of LGVN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, LGVN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year LGVN has reported negative net income.
LGVN had a negative operating cash flow in the past year.
In the past 5 years LGVN always reported negative net income.
LGVN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LGVN's Return On Assets of -137.18% is on the low side compared to the rest of the industry. LGVN is outperformed by 82.39% of its industry peers.
LGVN has a Return On Equity of -214.14%. This is in the lower half of the industry: LGVN underperforms 68.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -137.18% | ||
| ROE | -214.14% | ||
| ROIC | N/A |
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LGVN's Gross Margin of 74.88% is amongst the best of the industry. LGVN outperforms 83.52% of its industry peers.
In the last couple of years the Gross Margin of LGVN has grown nicely.
LGVN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
2. Health
2.1 Basic Checks
LGVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
LGVN has more shares outstanding than it did 1 year ago.
LGVN has more shares outstanding than it did 5 years ago.
LGVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -14.18, we must say that LGVN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of LGVN (-14.18) is worse than 78.41% of its industry peers.
There is no outstanding debt for LGVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.18 |
ROIC/WACCN/A
WACC8.82%
2.3 Liquidity
A Current Ratio of 2.09 indicates that LGVN has no problem at all paying its short term obligations.
The Current ratio of LGVN (2.09) is worse than 74.62% of its industry peers.
A Quick Ratio of 2.09 indicates that LGVN has no problem at all paying its short term obligations.
LGVN has a Quick ratio of 2.09. This is in the lower half of the industry: LGVN underperforms 72.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.09 | ||
| Quick Ratio | 2.09 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 76.27% over the past year.
LGVN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -22.41%.
Measured over the past years, LGVN shows a very negative growth in Revenue. The Revenue has been decreasing by -15.76% on average per year.
EPS 1Y (TTM)76.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.71%
Revenue 1Y (TTM)-22.41%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%-82.28%
3.2 Future
LGVN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.91% yearly.
Based on estimates for the next years, LGVN will show a very strong growth in Revenue. The Revenue will grow by 74.82% on average per year.
EPS Next Y64.14%
EPS Next 2Y29.67%
EPS Next 3Y16.91%
EPS Next 5YN/A
Revenue Next Year-47.8%
Revenue Next 2Y-43.23%
Revenue Next 3Y74.82%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LGVN. In the last year negative earnings were reported.
Also next year LGVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LGVN's earnings are expected to grow with 16.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.67%
EPS Next 3Y16.91%
5. Dividend
5.1 Amount
LGVN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
0.5719
-0.05 (-8.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners8.67%
Inst Owner Change0.01%
Ins Owners8.82%
Ins Owner Change6.24%
Market Cap12.20M
Revenue(TTM)1.44M
Net Income(TTM)-21.34M
Analysts82.5
Price Target7 (1123.99%)
Short Float %7.91%
Short Ratio3.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.86%
Min EPS beat(2)-49.94%
Max EPS beat(2)8.22%
EPS beat(4)1
Avg EPS beat(4)-16.87%
Min EPS beat(4)-49.94%
Max EPS beat(4)8.22%
EPS beat(8)3
Avg EPS beat(8)-18.04%
EPS beat(12)3
Avg EPS beat(12)-16.17%
EPS beat(16)5
Avg EPS beat(16)-11.14%
Revenue beat(2)0
Avg Revenue beat(2)-39.57%
Min Revenue beat(2)-52.82%
Max Revenue beat(2)-26.32%
Revenue beat(4)0
Avg Revenue beat(4)-31.04%
Min Revenue beat(4)-52.82%
Max Revenue beat(4)-7.27%
Revenue beat(8)2
Avg Revenue beat(8)140.83%
Revenue beat(12)2
Avg Revenue beat(12)81.18%
Revenue beat(16)5
Avg Revenue beat(16)72.18%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-56.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-44.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.49 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.22 | ||
| P/tB | 1.59 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.49
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.07
BVpS0.47
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -137.18% | ||
| ROE | -214.14% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.88% | ||
| FCFM | N/A |
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
F-Score4
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 54.96% | ||
| Cap/Sales | 45.51% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.09 | ||
| Quick Ratio | 2.09 | ||
| Altman-Z | -14.18 |
F-Score4
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)90.92%
Cap/Depr(5y)89.88%
Cap/Sales(3y)69.8%
Cap/Sales(5y)62.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.71%
EPS Next Y64.14%
EPS Next 2Y29.67%
EPS Next 3Y16.91%
EPS Next 5YN/A
Revenue 1Y (TTM)-22.41%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%-82.28%
Revenue Next Year-47.8%
Revenue Next 2Y-43.23%
Revenue Next 3Y74.82%
Revenue Next 5YN/A
EBIT growth 1Y-25.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.41%
OCF growth 3YN/A
OCF growth 5YN/A
LONGEVERON INC-A / LGVN FAQ
What is the ChartMill fundamental rating of LONGEVERON INC-A (LGVN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to LGVN.
Can you provide the valuation status for LONGEVERON INC-A?
ChartMill assigns a valuation rating of 0 / 10 to LONGEVERON INC-A (LGVN). This can be considered as Overvalued.
How profitable is LONGEVERON INC-A (LGVN) stock?
LONGEVERON INC-A (LGVN) has a profitability rating of 1 / 10.
How financially healthy is LONGEVERON INC-A?
The financial health rating of LONGEVERON INC-A (LGVN) is 5 / 10.